Analysis of the clinical use of antiviral treatment in patients taking into account the morphological mechanisms of growth of glial tumors contaminated with herpes simplex virus

INTRODUCTION. The general strategy for the growth of neuroepithelial tumors is a cascade of changes in the biological behavior of tumor cells and vascular endothelium that occur during the progression of the tumor process, taking into account transformation. MATERIALS AND METHODS. The study material included current and archival biopsies of 780 highly malignant glial tumors contaminated with herpes simplex virus (HSV). To detect HSV in tumors, an immunohistochemical (IHC) study was performed with antibodies to the HSV antigen. The control groups consisted of tumors that did not express antibodies to HSV and in which intranuclear inclusions characteristic of HSV were not detected. RESULTS. High-grade glial tumors, which include glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma, showed staged growth. The growth rate was determined by the ratio of growth factors, which include primarily the ratio of apoptotic p53 and anti-apoptotic factor bcl-2, the index of proliferative activity, as well as the number of vessels in the most vascularized (“hot”) spot. Part of the viral genome that entered the tumor and endothelial cells changed the growth rate of the host cell population. The productive inflammation that occurs in response to changes in the host cell genome stimulates proliferation processes, changing the rate of apoptosis. During the study, a method of using etiopathogenetic antiviral treatment was proposed. CONCLUSION. The significance of the HSV genome for glial tumors is enormous. It tries to preserve the tumor cell, on the one hand, but sharply increases the ability of the endothelium to divide during the joint replication of genetic material, on the other hand. The result of the proven complex mechanism of growth of glial tumors was the method of etiopathogenic antiviral treatment, which made it possible to extend the relapse-free period by an average of two times for all groups of high-grade gliomas.